[Current developments and perspectives in targeted therapies]

Onkologie. 2010:33 Suppl 5:2-11. doi: 10.1159/000313971. Epub 2010 May 14.
[Article in German]

Abstract

Many different approaches for improving the prognosis of patients with advanced non-small-cell lung cancer (NSCLC) are currently being investigated. This article discusses the significance of maintenance therapy after primary chemotherapy and reviews study data on second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), inhibitors of insulin-like growth factor receptors (IGFR), vascular-disrupting agents (VDAs) and multi-TKIs of vascular endothelial growth factor receptors (VEGFR). The article also looks at the future prospects of using genetic markers in the field of NSCLC.

Publication types

  • Review

MeSH terms

  • Aftercare
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / blood supply
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • DNA Mutational Analysis
  • Drug Delivery Systems*
  • Drugs, Investigational / administration & dosage*
  • Drugs, Investigational / adverse effects
  • ErbB Receptors / analysis*
  • ErbB Receptors / genetics
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Genetic Markers / genetics
  • Humans
  • Lung Neoplasms / blood supply
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Neoplasm Staging
  • Oncogene Proteins, Fusion / genetics
  • Prognosis
  • Protein-Tyrosine Kinases / genetics
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Somatomedin / antagonists & inhibitors
  • Receptors, Somatomedin / genetics
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / genetics

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • Genetic Markers
  • Oncogene Proteins, Fusion
  • Receptors, Somatomedin
  • Anaplastic Lymphoma Kinase
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor